Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study
| Autor: | Sayako Akiyama, Masahiro Yasaka, Emi Watanabe-Fujinuma, Yutaka Okayama, Yukihiro Koretsune, Shinichiro Uchiyama, Benjamin Banderas, Takeshi Yamashita, Stefan J. Cano, Koichiro Kumagai, Gavin Dickie, Jean-Baptiste Briere |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Non valvular atrial fibrillation 030204 cardiovascular system & hematology Treatment satisfaction 03 medical and health sciences 0302 clinical medicine Japan Rivaroxaban Internal medicine Atrial Fibrillation medicine Humans Patient Reported Outcome Measures Prospective Studies cardiovascular diseases 030212 general & internal medicine Stroke Aged Aged 80 and over business.industry Warfarin Anticoagulants Atrial fibrillation General Medicine Middle Aged medicine.disease Patient Satisfaction cardiovascular system Cardiology Female Observational study business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 34:2157-2164 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2018.1507315 |
| Popis: | Rivaroxaban has previously been shown to be as efficacious and safe as warfarin for the prevention of stroke in non-valvular atrial fibrillation (NVAF). Therefore, treatment satisfaction becomes an important consideration. Here we examine treatment satisfaction in Japanese NVAF patients who were switched from warfarin to rivaroxaban.Patient-reported outcome (PRO) data were collected as part of a prospective, multi-center, post-marketing surveillance (PMS) of a direct oral-anticoagulant, rivaroxaban, in Japan. The Anti-Clot Treatment Scale (ACTS) and the Treatment Satisfaction Questionnaire for Medication version II (TSQM-II) were collected at baseline, month 3, and month 6. Change in scores from baseline to month 3 and month 6 were assessed. Exploratory analyses included change in scores by patient characteristics. Safety and effectiveness of rivaroxaban were also assessed.ACTS Burdens scores significantly improved at month 3 (54.6 ± 6.3) and month 6 (54.5 ± 6.5) compared to baseline (51.0 ± 7.6) (p .001). ACTS Benefits score remained stable over time (baseline = 10.1 ± 2.8, month 3 = 10.2 ± 3.1, month 6 = 10.1 ± 3.1). Mean TSQM-II sub-scale scores significantly improved at month 3 and month 6 compared to baseline for all four domains (all p .001).Findings suggest treatment satisfaction may improve in Japanese NVAF patients after a switch from warfarin to rivaroxaban. Higher treatment satisfaction may translate into improved treatment adherence, which is critical for the long-term prevention of stroke. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|